Neil Gibson, PH.D.

Senior Advisor

Dr. Gibson, currently serves as the CEO of Adanate and was the CEO of PDI Therapeutics (recently transacted with Cullinan). Dr. Gibson has held various senior positions within the biotechnology and pharmaceutical industry including Senior Vice President of BioAtla; Chief Scientific Officer of Regulus Therapeutics; Chief Scientific Officer and Oncology Therapeutic Area Head of Pfizer Oncology; and Chief Scientific Officer of OSI Pharmaceuticals. While at Pfizer, Dr. Gibson was also a member of the Pfizer Oncology Business Unit Executive team. Dr. Gibson has been involved in the successful discovery, development, and commercialization of multiple therapeutic agents in cancer, diabetes, HCV, fibrosis, and NASH.

Avalon Bioventures